1. Home
  2. DYCQ vs SGMT Comparison

DYCQ vs SGMT Comparison

Compare DYCQ & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYCQ
  • SGMT
  • Stock Information
  • Founded
  • DYCQ 2022
  • SGMT 2006
  • Country
  • DYCQ United Kingdom
  • SGMT United States
  • Employees
  • DYCQ N/A
  • SGMT N/A
  • Industry
  • DYCQ
  • SGMT
  • Sector
  • DYCQ
  • SGMT
  • Exchange
  • DYCQ Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • DYCQ 93.1M
  • SGMT 93.7M
  • IPO Year
  • DYCQ 2024
  • SGMT 2023
  • Fundamental
  • Price
  • DYCQ $10.38
  • SGMT $4.50
  • Analyst Decision
  • DYCQ
  • SGMT Strong Buy
  • Analyst Count
  • DYCQ 0
  • SGMT 5
  • Target Price
  • DYCQ N/A
  • SGMT $21.60
  • AVG Volume (30 Days)
  • DYCQ 11.5K
  • SGMT 720.9K
  • Earning Date
  • DYCQ 01-01-0001
  • SGMT 11-13-2024
  • Dividend Yield
  • DYCQ N/A
  • SGMT N/A
  • EPS Growth
  • DYCQ N/A
  • SGMT N/A
  • EPS
  • DYCQ 0.26
  • SGMT N/A
  • Revenue
  • DYCQ N/A
  • SGMT N/A
  • Revenue This Year
  • DYCQ N/A
  • SGMT N/A
  • Revenue Next Year
  • DYCQ N/A
  • SGMT N/A
  • P/E Ratio
  • DYCQ $40.34
  • SGMT N/A
  • Revenue Growth
  • DYCQ N/A
  • SGMT N/A
  • 52 Week Low
  • DYCQ $10.07
  • SGMT $2.39
  • 52 Week High
  • DYCQ $10.43
  • SGMT $20.71
  • Technical
  • Relative Strength Index (RSI)
  • DYCQ N/A
  • SGMT 40.28
  • Support Level
  • DYCQ N/A
  • SGMT $4.19
  • Resistance Level
  • DYCQ N/A
  • SGMT $6.40
  • Average True Range (ATR)
  • DYCQ 0.00
  • SGMT 0.50
  • MACD
  • DYCQ 0.00
  • SGMT -0.23
  • Stochastic Oscillator
  • DYCQ 0.00
  • SGMT 14.03

About DYCQ DT Cloud Acquisition Corporation Ordinary Shares

DT Cloud Acquisition Corp is a newly incorporated blank check company.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Share on Social Networks: